Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Advances deployment of mRNA technology across vaccines and therapeutics development
It is part of the company’s pain/analgesics portfolio of OTC products
The company also plans to register the similar range of products in the neighbouring countries.
Subscribe To Our Newsletter & Stay Updated
